XML 51 R111.htm IDEA: XBRL DOCUMENT v2.4.1.9
Collaborative and Other Relationships (Details) (USD $)
 3 Months Ended 12 Months Ended
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Revenues from unconsolidated joint business                      
Revenue on sales in the rest of world for RITUXAN $ 2,287,000,000us-gaap_SalesRevenueGoodsNet [1] $ 2,117,300,000us-gaap_SalesRevenueGoodsNet $ 2,056,300,000us-gaap_SalesRevenueGoodsNet [2] $ 1,742,800,000us-gaap_SalesRevenueGoodsNet [3] $ 1,607,100,000us-gaap_SalesRevenueGoodsNet $ 1,453,600,000us-gaap_SalesRevenueGoodsNet $ 1,385,900,000us-gaap_SalesRevenueGoodsNet $ 1,095,800,000us-gaap_SalesRevenueGoodsNet $ 8,203,404,000us-gaap_SalesRevenueGoodsNet $ 5,542,331,000us-gaap_SalesRevenueGoodsNet $ 4,166,074,000us-gaap_SalesRevenueGoodsNet
Total unconsolidated joint business revenues 304,500,000biib_UnconsolidatedJointBusiness [1] 290,700,000biib_UnconsolidatedJointBusiness 303,300,000biib_UnconsolidatedJointBusiness [2] 296,900,000biib_UnconsolidatedJointBusiness [3] 269,400,000biib_UnconsolidatedJointBusiness 303,200,000biib_UnconsolidatedJointBusiness 288,800,000biib_UnconsolidatedJointBusiness 264,600,000biib_UnconsolidatedJointBusiness 1,195,389,000biib_UnconsolidatedJointBusiness 1,126,017,000biib_UnconsolidatedJointBusiness 1,137,923,000biib_UnconsolidatedJointBusiness
U.S                      
Revenues from unconsolidated joint business                      
Revenue on sales in the rest of world for RITUXAN                 5,566,700,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_StatementGeographicalAxis
= country_US		 3,581,000,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_StatementGeographicalAxis
= country_US		 2,176,800,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_StatementGeographicalAxis
= country_US
Roche Group - Genentech                      
Revenues from unconsolidated joint business                      
Total unconsolidated joint business revenues                 1,195,400,000biib_UnconsolidatedJointBusiness
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 1,126,000,000biib_UnconsolidatedJointBusiness
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 1,137,900,000biib_UnconsolidatedJointBusiness
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember
Roche Group - Genentech | U.S                      
Revenues from unconsolidated joint business                      
Biogen Idec's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA                 1,114,100,000biib_ShareOfCoPromotionProfits
/ us-gaap_StatementGeographicalAxis
= country_US
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 1,085,200,000biib_ShareOfCoPromotionProfits
/ us-gaap_StatementGeographicalAxis
= country_US
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 1,031,700,000biib_ShareOfCoPromotionProfits
/ us-gaap_StatementGeographicalAxis
= country_US
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember
Reimbursement of our selling and development expenses in the U.S. for RITUXAN                 3,000,000biib_ReimbursementOfSellingAndDevelopmentExpenses
/ us-gaap_StatementGeographicalAxis
= country_US
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 2,100,000biib_ReimbursementOfSellingAndDevelopmentExpenses
/ us-gaap_StatementGeographicalAxis
= country_US
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 1,600,000biib_ReimbursementOfSellingAndDevelopmentExpenses
/ us-gaap_StatementGeographicalAxis
= country_US
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember
GAZYVA                      
After First GA101 Threshold Date                      
Until First GAZYVA Threshold Date 39.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
/ us-gaap_ProductOrServiceAxis
= biib_GAZYVAMember		               39.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
/ us-gaap_ProductOrServiceAxis
= biib_GAZYVAMember		    
After First Threshold Date and until Second Threshold Date 37.50%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
/ us-gaap_ProductOrServiceAxis
= biib_GAZYVAMember		               37.50%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
/ us-gaap_ProductOrServiceAxis
= biib_GAZYVAMember		    
After Second Threshold Date 35.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
/ us-gaap_ProductOrServiceAxis
= biib_GAZYVAMember		               35.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
/ us-gaap_ProductOrServiceAxis
= biib_GAZYVAMember		    
RITUXAN                      
Co-promotion profit sharing formula                      
Until GAZYVA First Non-CLL FDA Approval 40.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		               40.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		    
After First GA101 Threshold Date                      
Until First GAZYVA Threshold Date 39.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		               39.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		    
After First Threshold Date and until Second Threshold Date 37.50%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		               37.50%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		    
After Second Threshold Date 35.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		               35.00%biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember		    
RITUXAN | Roche Group - Genentech | Outside the U.S                      
Revenues from unconsolidated joint business                      
Revenue on sales in the rest of world for RITUXAN                 $ 78,300,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember
/ us-gaap_StatementGeographicalAxis
= us-gaap_ForeignCountryMember
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 $ 38,700,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember
/ us-gaap_StatementGeographicalAxis
= us-gaap_ForeignCountryMember
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember		 $ 104,600,000us-gaap_SalesRevenueGoodsNet
/ us-gaap_ProductOrServiceAxis
= biib_RituxanMember
/ us-gaap_StatementGeographicalAxis
= us-gaap_ForeignCountryMember
/ us-gaap_TypeOfArrangementAxis
= biib_RocheGroupGenentechMember
[1] Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.
[2] Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of all remaining rights to TYSABRI from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.
[3] Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.